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AAV-DJ, a leading candidate vector for liver gene
therapy, was created through random homologous
recombination followed by directed evolution,
selecting for in vivo liver tropism and resistance to
in vitro immune neutralization. Here, the 4.5 A˚ resolu-
tion cryo-EM structure is determined for the engi-
neered AAV vector, revealing structural features
that illuminate its phenotype. The heparan sulfate
receptor-binding site is little changed from AAV-2,
and heparin-binding affinity is similar. A loop that is
antigenic in other serotypes has a unique conforma-
tion in AAV-DJ that would conflict with the binding of
an AAV-2 neutralizing monoclonal antibody. This is
consistent with increased resistance to neutraliza-
tion by human polyclonal sera, raising the possibility
that changed tropism may be a secondary effect of
altered immune interactions. The reconstruction
exemplifies analysis of fine structural changes and
the potential of cryo-EM, in favorable cases, to char-
acterize mutant or ligand-bound complexes.
INTRODUCTION
Adeno-associated virus (AAV) holds much promise in its devel-
opment as a vector for human gene therapy (Carter et al.,
2008). Gene therapy involves the delivery to targeted cells of
DNA designed to alleviate a genetic disease ormitigate a genetic
predisposition by, for example, providing a fully functional
replacement for a mutated gene (Schambach et al., 2008).
Dozens of clinical trials have safely taken advantage of the
features of AAV vectors, with efficacy demonstrated in treat-
ments for congenital blindness and Parkinson’s disease, along
with encouraging results with factor IX treatments for hemophilia
B and other diseases (High and Aubourg, 2011; Nathwani et al.,
2011). Challenges remain, including the targeting of vectors to
specific cells and efficient delivery, while avoiding a neutralizing
immune response (Bu¨ning et al., 2003; Calcedo et al., 2009).1310 Structure 20, 1310–1320, August 8, 2012 ª2012 Elsevier Ltd AlAAV is a 25-nm-diameter nonenveloped virus containing
a 5 kb single-stranded DNA genome surrounded by a protein
capsid (Muzyczka and Berns, 2001). The crystal structure of
the type species serotype 2 (AAV-2) revealed a T = 1 icosahe-
drally symmetric structure with 60 subunits, each of which had
a core b-barrel, decorated by long surface loops that intertwined
with those of neighbors to form prominent spikes surrounding
the 3-fold axes (Xie et al., 2002). Crystal structures for the other
predominant human serotypes followed, as well as for several
whose primary host may be simian (Govindasamy et al., 2006;
Lerch et al., 2010; Nam et al., 2007; Ng et al., 2010; Xie et al.,
2011). Cryo-electron microscopy (EM) at 8 A˚ resolution has
been used to visualize an analog of AAV-20s primary (attachment)
cell receptor, heparan sulfate proteoglycan (HSPG) (Summer-
ford and Samulski, 1998), bound on the side of the spikes
(O’Donnell et al., 2009). Intriguingly, two arginines within
a peptide known as the heparin-binding domain (HBD) (Kern
et al., 2003; Opie et al., 2003; Xie et al., 2002) are not conserved
in other AAV serotypes. A combination of crystallography and
mutagenesis has recently established that other human sero-
types use analogous, but distinct, clusters of positively charged
residues for attachment to the cell surface receptor (Lerch
and Chapman, 2012; Xie et al., 2011). The spikes and
surrounding exposed regions are also themost antigenic regions
to which neutralizing antibodies are thought to bind (Lochrie
et al., 2006).
The atomic structures have provided a foundation for the
development of gene therapy vectors with altered cellular spec-
ificity. Rational insertion of peptide ligands for nonnative cellular
receptors has shown promise (Girod et al., 1999; Shi and
Bartlett, 2003), but faster progress wasmade using in vitro selec-
tion of new tropism from populations of particles with random-
ized peptide sequences inserted strategically into exposed
loops near the HSPG-binding region of the spikes (Mu¨ller et al.,
2003; Perabo et al., 2003). Recent excitement has come with
exploitation of phenotypic variation among the natural serotypes
through selection among variants created by random gene shuf-
fling or homologous recombination (Grimm et al., 2008; Li et al.,
2008; Yang et al., 2011).
The current study focuses on AAV-DJ, the variant that first
demonstrated the value of gene shuffling in vector developmentl rights reserved
Figure 1. Representative Coulomb Potential Density from the 3D
Cryo-EM Reconstruction at 4.5 A˚ Resolution, Compared to Corre-
sponding Regions of the 3.0 A˚ Crystallographic Electron Density of
AAV-2, Truncated at the Same Resolution
The crystallographic map has been calculated with model-independent
phases obtained through extension / refinement using 60-fold noncrystallo-
graphic symmetry (Xie et al., 2003).
(A and B) Part of the clearly traceable b-barrel (A) and representative aromatic
side chains (B) fit to the maps of AAV-DJ (left) and AAV-2 (right). Maps are
contoured at 1.7–1.2 s to cover comparable volumes.
(C) The weakest density for the entire AAV-DJ structure is a loop containing
residues 453–458. Strong, but discontinuous, density is observed at a contour
of 1 s (left), but the loop is fully traceable at a lower contour (right).
See also Figure S1.
Structure
Cryo-EM Structure of AAV-DJ(Grimm et al., 2008). From libraries of AAV hybrids of eight sero-
types, variants were first selected for in vitro entry into human
hepatoma cell lines (that have low natural permissiveness for
AAV) and then for resistance to human antisera. After five
passages in the presence of pooled human antisera (IVIG), which
had neutralizing activity against a broad range of serotypes,
sequencing of 96 clones revealed enrichment with a single
AAV-2/8/9 chimera that shared >85% sequence identity to the
parental strains, differing from its closest relative (AAV-2) by 60
capsid amino acids (8%). AAV-DJ has the desired increased tar-
geting of liver cells, combining the best features of AAV-2 with
those of AAV-8 and AAV-9. Like AAV-2, it is able to efficiently
transduce a broad range of cell types in vitro but has specific liver
tropism in vivo, and like AAV-8 and AAV-9, it is better able to
evade immune neutralization and efficiently deliver higher quan-
tities of therapeutic DNA (Grimm et al., 2008). The means with
which these properties have beenmodulated are not fully under-
stood. Mutational studies showed that the HBD from AAV-2 was
key to strong in vitro cell attachment and transduction efficiency,
which was up to 105-fold greater than with AAV-8 and AAV-9
(Grimm et al., 2008). However, cell attachment is not the only
determinant of in vitro transduction, as AAV-DJ transduction effi-
ciency exceeded that of AAV-2, in spite of reduced cell attach-
ment (Grimm et al., 2008). In vivo, AAV-DJ yielded human factor
IX expression levels in mouse liver 20-fold greater than AAV-2
and equivalent to those of the best natural serotypes, AAV-8
and AAV-9 (Grimm et al., 2008). Intriguingly, mutation showed
that efficient liver transduction was not dependent on the HBD,
as it is in AAV-2. The HBD was, however, important in AAV-DJ’s
more restricted tropism, like AAV-2, with little DNA detectable
in the brain, pancreas, gut, and muscle (Grimm et al., 2008).
Thus, tropism and the role of the HBD appear to bemultifaceted.
In fact, there is evidence that in vivo tissue tropism of AAV
depends not only on direct interactions with the target cell but
also on ability to cross capillary walls and clearance from the
blood (Kotchey et al., 2011).
Here, we report the atomic structure of AAV-DJ as determined
by cryo-EM, revealing a capsid loop conformation that is distinct
from the natural AAVs of known structure. The structure allows
us to rationalize some of the novel properties of the vector,
provides a foundation for further characterization and develop-
ment of next-generation vectors, and provides mechanistic
insights into the process of directed evolution.
RESULTS
Structural studies were initiated by X-ray crystallography and
cryo-electron microscopy (EM) in parallel. Three crystal forms
of AAV-DJ VLPs diffracted to 7, 5, and 5 A˚ resolution, respec-
tively. Although the backbone could be traced (Supplemental
Experimental Procedures available online), cryo-EM took prece-
dence when maps showed superior definition of side chains and
flexible loops.
Cryo-EM Reconstruction
Using the Leginon software package, 4,773 images of ice-
embedded AAV-DJ were collected automatically. CTF was esti-
mated using Appion, and 36,280 particles were manually
selected for single-particle reconstruction. FREALIGN (Grigor-Structure 20, 1310ieff, 2007) was used for the single-particle refinement, and
27,312 particles were used in the final three-dimensional (3D)
reconstruction. The resolution for the final volumewas estimated
to be between 4.5 A˚ (FSC0.143) and 5.3 A˚ (FSC0.5). Relative to an
earlier EMAN reconstruction (Ludtke et al., 1999) using 17,721
particles, subtle improvements could be seen in the reconstruc-
tion, when compared to the atomicmodel, with some side chains
slightly better defined. The new reconstruction supported
a modestly improved atomic refinement (see ‘‘Model Building
and Refinement’’), but, more importantly, two external loops,
near residues 457 and 266 become fully resolved (Figures 1C
and 3B).–1320, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1311
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Atomic modeling started with refinement of the relative magnifi-
cation for the AAV-DJ reconstruction against the crystal struc-
ture of homolog, AAV-2. Accurate least-squares refinement of
the magnification was critical to success of the atomic refine-
ment. Evaluated with the final model/EM reconstruction, this
1% correction of the magnification moves density 1.3 A˚ on the
outside of the virus and improves the model-density correlation
coefficient from 0.71 to 0.87. The need for a correction as large
as 1.0111 may have resulted from use of a newly commissioned
microscope and interpolation of the magnification from sparsely
sampled voltage/magnification calibration curves.
Atomic refinement used a new implementation of the real-
space refinement RSRef (Chapman, 1995), embedded in CNS
(Bru¨nger et al., 1998). The latter provided a force field potential
for stereochemical restraint and support for optimizations by
conjugate gradients or reduced parameter simulated annealing
torsion angle dynamics. Salient features of the new RSRef
implementation include full support for molecular symmetry
constraints and optimization not only of the atomic coordinates
but the EMmagnification (see previous paragraph), an exponen-
tial EM envelope function, and the ‘‘soft’’ resolution limit of a fifth
order Butterworth low-pass filter (Frank et al., 1996). All of these
parameters are optimized by minimizing the difference between
density calculated from the atomic model and the reconstructed
density. Optimization of a non-Gaussian low-pass filter sup-
ported refinement against more detailed maps corrected for
instrument attenuation by sharpening with EM-Bfactor (Ferna´n-
dez et al., 2008). (Following such corrections, the high-resolution
fall-off in signal is unlikely to remain strictly Gaussian). For
AAV-DJ, parameters of the low-pass filter have modest impact,
affecting the final correlation coefficient by 1%.
Crystallographic structures at resolutions coarser than 4 A˚
have demonstrated the potential for refinement, providing that
initial structures are based on those of high-resolution homologs,
and that additional stereochemical restraints are used to limit the
degrees of freedom (Bru¨nger et al., 2009; Schro¨der et al., 2010).
In the AAV-DJ refinement, a force field component was added to
restrain the backbone dihedral angles 4 and c. Following the
lead of several prior investigations, additional dihedral restraints
were specified in CNS. However, instead of restraining to the
starting values, flat-bottom potential wells (Bru¨nger, 1992)
were specified for each amino acid to restrain 4 and c toward
the closest-favored region of a Ramachandran plot. This was
particularly important for the external loops, where changes
from the AAV8-based starting model would be required (see
Experimental Procedures). With little impact on the correlation
coefficients, the restraint corrected a tendency for the backbone
dihedrals to deviate from reasonable values. In the final
model, >99%of amino acids fall in the favored/allowable regions
of the Ramachandran plot (Laskowski et al., 1993), and the
remainder are close to the boundaries (Figure S2).
Isotropic atomic B-factors were refined using RSRef with
a strong restraint on the difference between bonded neighbors
(Konnert and Hendrickson, 1980). The resulting RMS deviation
between neighboring B-factors (8.5 A˚2) was less than that refined
for the crystallographic AAV-8 (8.7 A˚2) and AAV-2 (9.5 A˚2) struc-
tures. As to be expected in a low-resolution refinement, variation
in individual thermal parameters had only subtle impact on the1312 Structure 20, 1310–1320, August 8, 2012 ª2012 Elsevier Ltd Alquality of fit (CC improved 0.6%). Increased correlation resulted
in part from locally improved backbone, where higher B-factors
allowed the structure to relax rather than force a fit to weaker
density. The correlation coefficient between individual B-factors
from AAV-DJ and the AAV-2/-8 crystal structures (0.5) is slightly
lower than between the crystal structures (0.6). However, there
are similar patterns of relative disorder/flexibility, particularly
for the external loops (Figure S3). Thus, although little confidence
can be placed in individual B-factors refined at this resolution,
with heavy restraint, they provide a useful regional indicator of
the level of order.
Resolution and Final Model Quality
In the absence of established methods for cross-validating
EM-fitted atomic models, we fall back to classical (pre-1993)
assessments of the fit of model to data and of the tightness of
restraints that guard against overfitting during refinement.
Reflecting the tight stereochemical restraints, RMS deviations
from standard stereochemistry are small: 0.009 A˚ for bond
lengths and 1.5 for bond angles, and the 0.5% of Ramachan-
dran outliers (Figure S2) falls within the best quartile of crystal
structures below 3.5 A˚ resolution (Read et al., 2011).
The final correlation coefficient between atomic model and
reconstruction was calculated by RSRef to be 0.884. The numer-
ical value reported by many programs depends on parameters
that (indirectly) affect the volume of the reconstruction used in
calculation of the correlation coefficient, and the value can be
increased either by including more uniform density far from
atoms or by restricting the comparison to stronger density near
atomic peaks. In RSRef, there is no need for ad hoc estimates
of the widths of assumed Gaussian atomic density functions,
because the density functions are calculated in reciprocal space
using the experimental resolution limits, atomic B-factors, and
experimental attenuation functions. Correlation coefficients still
depend upon the volume used, but the dependence is clear
and explicit. For AAV-DJ, all pixels were used within 4.5 A˚ of
any model atom, a distance commensurate with the nominal
resolution and large enough so that the correlation coefficient
was not highly sensitive to the cutoff. This criterion is more
stringent than those implied by the defaults of other programs,
and the numerical value of the correlation coefficient is lower
than the 0.92 reported by Chimera, for example (Pettersen
et al., 2004).
As biomolecular EMhas attained near-atomic resolution, there
have been increasing discussions of the effective resolution of
EM reconstructions (Jiang et al., 2008; Zhang et al., 2010).
Discussions have been framed largely around comparison of
the experimental density with generic features that one would
expect to see, say in a crystallographic structure of comparable
resolution. Here, we can add two perspectives: side-by-side
comparison of corresponding EM and crystallographic maps
(Figure 1) and estimation of the atomic model resolution that
best agrees with the EM map (next paragraph). A side-by-side
comparison is possible because of the availability of the highly
homologous AAV-2 crystal structure (Xie et al., 2002) (92%
capsid sequence identity). This may be preferable to compari-
sons that pair entirely different structures or compare map to
model-calculated density, because there is reason to hope that
the local levels of disorder in the two samples might bel rights reserved
Figure 2. The AAV-DJ Heparin Binding Region
(A) Surface electrostatic potential of AAV-DJ (left) compared to AAV-2 (right).
The molecular surface of the capsid spikes is colored from positive (blue) to
negative (red), viewed down the 3-fold symmetry axis (triangle). The AAV-2
heparin-binding footprint (O’Donnell et al., 2009) is outlined with HBD residues
Arg585/Arg588 (AAV-2) or Arg587/Arg590 (AAV-DJ) forming the most positively
charged part. The electrostatic potentials are similar with only subtle differ-
ences. Positive potential extends further above the HBD in AAV-DJ (arrows).
However, the immediate vicinity of the 3-fold (triangle) is slightly positively
charged in AAV-2 near where a heparin polymer would bridge between HBDs
and where AAV-3B’s Arg594 participates in binding (Lerch and Chapman,
2012).
(B) Heparin affinity chromatography reveals that AAV-DJ binds with slightly
weaker affinity than AAV-2, although it seems unlikely that the subtle differ-
ences in surface charge and heparin affinity fully explain the phenotype of
AAV-DJ. VLPswere eluted in PBS supplemented with the NaCl concentrations
shown, denatured, and detected by dot blot as described in the Experimental
Procedures.
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Cryo-EM Structure of AAV-DJcommensurate. Figure 1 indicates that the qualities of the EM
and crystallographic maps at 4.5 A˚ are indistinguishable.
Improvements over previous circa 4.5 A˚ resolution structures
(Jiang et al., 2008) can be noted, such as fully-resolved separa-
tion of adjacent b strands (4.8 A˚ apart; Figure 1A) and a larger
proportion of side chains resolved (Figure 1B). It is not clear
the extent to which improvements in the effective resolution
result from the different samples (i.e., bacteriophage ε15 and
AAV-DJ) or continuing improvements in EM technology over
the last few years. It should be noted that the icosahedral
symmetry greatly facilitates 3D reconstruction of both EM struc-
tures and effectively eliminates phase error from the crystallo-
graphic map (Arnold and Rossmann, 1986), so the discussion
pertains to best-case examples. However, this subjective
appraisal of the density indicates that (1) in favorable cases, an
intermediate resolution EM reconstruction can contain all of
the expected features and (2) (symmetry-averaged) cryo-EM
density can be of commensurate quality to a crystallographic
map calculated with phases refined (at high resolution) by
60-fold averaging—which will be of much higher quality than
typical maps phased experimentally or by molecular replace-
ment. The presence of high order symmetry allows modeling
and refinement of both crystallographic and cryo-EM structures
at lower resolutions than possible in more typical crystallo-
graphic structure determinations.
A further indication of resolution comes from refinement of the
parameters of a low-pass Butterworth filter applied to the model
density. The cutoff frequency corresponds to the resolution at
which the amplitude is half that of pass-through frequencies.
Thus, refinement of a cutoff for the model density provides an
estimate of the resolution at which correlated signal in the recon-
struction drops below 0.5. This is analogous to an FSC0.5, except
that known biases arising from alignment of image noise in FSC
estimation (Grigorieff, 2000) are replaced by a dependence on
how well a particular atomic model fits the reconstruction. For
cases such as AAV-DJ, where it is possible to fit a high-resolu-
tion atomic model, this is an advantage, because the refined
cutoff frequency provides an independent estimate of experi-
mental resolution, and it also gauges the quality of the final
atomic model. The parameters of the low-pass filter were some-
what covariant with a Gaussian envelope correction, and any
resolution limit previously imposed, in EM-Bfactor (Ferna´ndez
et al., 2008), for example, must be correctly specified. AAV-DJ
had been truncated at 4.5 A˚ (the FSC0.143 limit). Assuming that
the EM envelope function was fully corrected by EM-Bfactor,
the low-pass resolution of the Butterworth filter refined to
4.6 A˚, in excellent agreement with the 4.5 A˚ FSC0.143 value.
Electrostatics and the HSPG Binding Site
The primary attachment receptor for AAV-2, HSPG (Summerford
and Samulski, 1998) carries negatively charged sulfate groups.
Electrostatic surface potential, calculated from structure, has
proved to be a robust predictor of heparanoid-binding. Struc-
ture-based prediction of the AAV-2 binding site (Xie et al.,
2002) was confirmed through two independent mutagenesis
studies (Kern et al., 2003; Opie et al., 2003) and direct visualiza-
tion by cryo-EM (O’Donnell et al., 2009). Electrostatics was the
basis of hypotheses that AAV-3B and AAV-6 compensated for
the absence of AAV-20s Arg585 and Arg588 through some of theStructure 20, 1310other positively charged surface residues in the general area,
hypotheses that have now been affirmed through site-directed
mutagenesis and the crystal structure of a AAV-3/disaccharide
complex (Lerch and Chapman, 2012; Lerch et al., 2010; Xie
et al., 2011).
AAV-DJ contains the HBD from AAV-2, and the electrostatic
potential overall is quite similar to that of AAV-2 (Figure 2A).
They share a strongly positive patch on the inner surface of
each 3-fold proximal spike, where cryo-EM showed heparin to
be most strongly bound to AAV-2 (O’Donnell et al., 2009). The
similarity of the electrostatics may explain the superior transduc-
tion efficiency of AAV-DJ in 12 cultured cell lines, which is
matched most closely by AAV-2 and is orders of magnitude
better than other natural serotypes (Grimm et al., 2008).
The differences in AAV-DJ electrostatics relative to AAV-2 are
quite subtle. The region of positive charge extends from the HBD
further up the spike in AAV-DJ. However, immediately around
the 3-fold axis, the site of heparin-binding determinant Arg594
in AAV-3B (Lerch and Chapman, 2012), AAV-DJ has slightly
negative charge, in contrast to AAV-20s weak positive charge.
Consistent with their similar electrostatic surface potentials,
the heparin binding affinities of AAV-DJ and AAV-2 were found
to be comparable, as measured by affinity chromatography (Fig-
ure 2B). AAV-DJ has marginally weaker binding than AAV-2, as–1320, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1313
Figure 3. A Unique Loop Structure in AAV-DJ
(A) Local sequence alignment for the loop, where the
AAV-DJ structure is most distinct. The parental strains
AAV-2, AAV-8, and AAV-9 are in bold font where their
sequences are identical to AAV-DJ.
(B) The distinct 3D structure for this loop is highlighted
with this stereographic pair showing the AAV-DJ
structure (colored by atom type) superimposed on the
EM density. For comparison, the backbones of
parental serotypes of known structure are shown,
AAV-2 (red) and AAV-8 (blue).
(C) Alignment of all known AAV structures further
demonstrates the unique conformation of AAV-DJ at
VR-I. AAV-1 (pink; PDB ID 3NG9), AAV-2 (red) (Xie
et al., 2002), AAV-3B (orange) (Lerch et al., 2010), AAV-
4 (yellow) (Govindasamy et al., 2006), AAV-5 (wheat;
PDB ID 3NTT), AAV-6 (violet) (Xie et al., 2011), and
AAV-8 (blue) (Nam et al., 2007).
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Cryo-EM Structure of AAV-DJindicated by elution from a heparin column at slightly lower ionic
strength (PBS supplemented with 300–350mMNaCl for AAV-DJ
versus 350–400 mMNaCl for AAV-2). This observation is consis-
tent with the previous finding that AAV-DJ exhibits weaker cell
binding, compared to AAV-2 (Grimm et al., 2008). It is unlikely,
however, that the modest differences in electrostatics and
binding affinities for a cell-attachment receptor analog can fully
explain the unique phenotype of AAV-DJ. It seems more plau-
sible that regions more diverse in structure, as described in the
next section, would account for functional differences between
AAV-DJ and the natural serotypes.
Structural Differences at an Antigenic Site
The AAV-DJ structure differs most from the crystal structures of
AAV-2 and AAV-8 (Nam et al., 2007; Xie et al., 2002) at residues
451–470 and at residues 262–270, regions of variable sequence
among AAVs, designated variable regions (VR) IV and I, respec-
tively (Chapman and Agbandje-McKenna, 2006; Govindasamy
et al., 2006). The Ca RMS differences between AAV-DJ and
AAV-2 (4 A˚) and between AAV-DJ and AAV-8 (2.2 A˚2) at VR-IV1314 Structure 20, 1310–1320, August 8, 2012 ª2012 Elsevier Ltd All rights reservedare no greater than the deviations observed
in prior AAV structures at this most distal
loop from the viral center, which is believed
to be the most flexible region on the capsid
surface. VR-I (the surface-exposed part of
loop 1, between strands bB and bC), a region
where the AAV-DJ sequence is taken from
AAV-9 (Figure 3A), adopts a distinct confor-
mation. The density here was among the
weakest throughout the cryo-EM map, but
at low contours the unique structure of the
AAV-DJ backbone is clear (Figure 3B).
AAV-DJ and AAV-8 have the same number
of residues in VR-I, an insertion of two resi-
dues relative to AAV-2, but the local struc-
ture is unique to AAV-DJ with Ca RMS differ-
ences of 4.0 and 6.3 A˚ compared to AAV-2
and AAV-8, respectively. In AAV-3B, AAV-6,
and AAV-8, the B-factors of VR-I are
elevated (>60 A˚2), but for AAV-DJ, likeAAV-2 and AAV-4, they are closer to the subunit average
(30 A˚2). The sequence of the loop is identical to AAV-9, whose
structure is not yet known. Large structural deviations from the
AAV-8 loop, however, suggest that sequence and structural
similarity in this region are not necessarily correlated. A more
broad comparison to all other AAV serotypes of known structure
(AAV-1 to AAV-6 and AAV-8) shows that this region is not only
distinct from the parental AAV-2 and AAV-8 but is unique among
analogous sites on AAV-1, AAV-3, AAV-4, AAV-5, and AAV-6
(Govindasamy et al., 2006; Lerch et al., 2010; Nam et al., 2007;
Ng et al., 2010; Xie et al., 2011) (Figure 3C).
These structural differences are located at a site that would
be within the footprint of the AAV-2-neutralizing mouse mono-
clonal antibody (mAb) A20 (Figure 4A) (Wobus et al., 2000) as
visualized by cryo-EM (McCraw et al., 2012) and close to resi-
dues whose mutation leads to neutralization-escape (Lochrie
et al., 2006). The VR-I conformation would lead to steric conflict
in the binding of mAb A20 to AAV-DJ (Figure 4B). Indeed, mAb
A20 does not bind to AAV-DJ, even at very high concentrations
(Figure 4C), but binds specifically to assembled capsids of
Structure
Cryo-EM Structure of AAV-DJAAV-2 and AAV-3 (Wobus et al., 2000). The local difference of
4.0 A˚ between AAV-2 and AAV-DJ, capsids that are overall
92% identical in sequence, is greater than the difference of
1.3 A˚ between serotypes 2 and 3 (87% capsid sequence
identity) that are both recognized by mAb A20. Functionally,
mAb A20 models some of the dominant interactions with human
polyclonal sera (Lochrie et al., 2006), so its epitope likely has
broad significance in AAV immune neutralization. VR-I is the
site of by far the greatest differences between AAV-2 and
AAV-DJ, likely accounting for most, if not all of AAV-DJ’s
resistance to pooled human serum (IVIG) that has highest
neutralizing activity against AAV serotypes 2 and 3 (Grimm
et al., 2008).
DISCUSSION
AAV-DJ met the objectives of the study by Grimm and
colleagues in establishing the feasibility of using gene shuffling
to improve the properties of a gene therapy vector. AAV-DJ
had improved transduction in liver and other cells (over AAV-2)
with higher tissue specificity than AAV-8 or AAV-9 (Grimm
et al., 2008; Inagaki et al., 2006; Nakai et al., 2005). In the
absence of other information, changes in tropism might be
expected to be mediated through interactions with extracellular
receptors. However, AAV-DJ differs only subtly from AAV-2 in
the HSPG attachment footprint (O’Donnell et al., 2009) and
most other parts of the viral surface. The liver specificity shared
by AAV-DJ and AAV-2 is indeed dependent on the HBD in both
serotypes (Girod et al., 1999; Grimm et al., 2008). However, the
greatest difference between AAV-2 and AAV-DJ, resulting from
the directed evolution, is in the conformation of VR-I, within the
footprint of the mouse neutralizing mAb A20. Steric conflict
between A20 and this loop of AAV-DJ would explain AAV-DJ’s
resistance to A20-binding and resistance to human polyclonal
neutralization, if prevalent human neutralizing antibodies bind
in a similar manner. It is possible that VR-I is a dominant neutral-
izing epitope due to proximity to unknown binding sites of one of
the coreceptors (Agbandje-McKenna and Kleinschmidt, 2011) or
other interactions important to trafficking in specific cells.
Recent studies suggest that AAV serotypes, all of which vary
structurally at VR-I, use several serotype-specific coreceptors
for cell entry (Akache et al., 2006; Di Pasquale and Chiorini,
2003; Kashiwakura et al., 2005; Ling et al., 2010; Qing et al.,
1999). Delayed blood clearance has been implicated in cardiac
transduction of AAV-9 (Kotchey et al., 2011), so it is also plau-
sible that modulation of immune interactions at a dominant
neutralizing epitope could be contributing to greater differences
in biodistribution than might be expected from in vitro cellular
transduction efficiencies (Grimm et al., 2008). Just as the
HSPG attachment site has emerged as having multiple roles
(Grimm et al., 2008), there may be multiple effects of modulating
the structure near VR-I so that it too contributes to in vivo
tropism.
The structural results give some insights into the directed
evolution used to generate AAV-DJ. A library of random homol-
ogous recombinants was put through five passages with posi-
tive selection of viruses that could replicate in liver cells and
negative selection for virions that escaped neutralization by
human intravenous immunoglobulin (IVIG) (Lochrie et al.,Structure 20, 13102006). With positive selection alone, there was 16-fold enrich-
ment of strains containing the HBD, but the pool remained highly
diverse. It was the presence of neutralizing IVIG that was more
selective, yielding a single sequence among 96 clones after
five passages. VR-I, the site of greatest differences between
AAV-2 and AAV-DJ, likely accounts for most of AAV-DJ’s resis-
tance to pooled human serum (IVIG) that is highly neutralizing
against prevalent human AAV serotypes. Thus, the most signif-
icant structural changes occurred as a result of the stronger
selective pressure and allowed one type of recombinant to
dominate completely.
Steric conflict between the AAV-DJ conformation of VR-I and
the binding site of mAb A20 in AAV-2 (Figure 3) offers more than
a rationalization of the observed specificity of mAb A20 (Grimm
et al., 2008). Escape from A20-binding can be engineered at
a number of sites (Lochrie et al., 2006). That perturbed conforma-
tion at just VR-I provided such strong selective advantage for
escape against polyclonal IVIG implies that epitopes to many
of the most neutralizing human antibodies overlap at VR-I. This
could, but need not imply that VR-I is a dominant neutralizing
immunogenic site. It is possible that other sites are neutralizing
immunogens but remained unchanged in the directed evolution
of AAV-DJ because of selective pressure to conserve an essen-
tial function in infecting liver cells. Indeed, comparison of the
mutagenesis data (Lochrie et al., 2006) with the heparin struc-
tural footprint (O’Donnell et al., 2009) suggests two putative
dominant epitopes in AAV-2 and AAV-DJ, one represented in
the interactions of mAb A20 that have been disrupted in AAV-DJ
and a second at the HSPGbinding site. One could speculate that
VR-I is selected as the site of greatest change in AAV-DJ
because it is not directly involved in an essential function but is
close enough to be part of the footprint of antibodies that
block said function. Separation of the changes at VR-I from
the heparin-binding footprint (Figure 4), together with the prior
understanding that mAb A20 inhibits a postattachment step
(Wobus et al., 2000), suggests that neutralizing antibodies
binding near VR-I may be inhibiting coreceptor binding or
some later step of infection.
Until recently, EM has been considered in some circles to
be the alternative to be used only when higher resolution X-ray
crystallography is not applicable because of sample size,
heterogeneity, disorder, or dynamics. This perception has
been challenged recently by a series of cryo-EM reconstructions
that have approached 3 A˚ resolution, once the exclusive domain
of crystallography (Cong et al., 2010; Jiang et al., 2008; Liu et al.,
2010; Ludtke et al., 2008; Yu et al., 2008; Zhang et al., 2010;
Zhou, 2008). A goal of such vanguard EM has been to establish
the feasibility of ab initio atomic structures by reaching resolu-
tions, where backbone can be traced unambiguously and
sequence threaded using recognizable side chain density.
Perhaps it is a favorable case, but the current reconstruction
provided an unambiguous backbone trace and enough side-
chain density for the threading of a known sequence, even at
4.5 A˚ resolution. Of greater note, the current study establishes
the feasibility of EM analysis of small changes to a large struc-
ture. Until now, difference structure analysis of mutants and
ligand complexes has been the exclusive domain of crystallog-
raphy. Here, it is demonstrated that a Ser-Gly (10 atom) insertion
and changes to the surrounding five amino acids can be–1320, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1315
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The ability to do this at 4.5 A˚ resolution probably stems from
direct imaging, avoiding the crystallographic need for phases
which would be estimated from the approximate atomic model
in conventional difference structure analysis.
EXPERIMENTAL PROCEDURES
Production of AAV-DJ
The capsid gene of AAV-DJ was amplified by PCR, introducing BglII and
XbaI restriction sites, digested, and subcloned into the backbone of
pFBDVPm11 plasmid, generously supplied by Robert Kotin (Urabe et al.,
2002). Mutations analogous to those described for AAV-2 (Urabe et al.,
2002) were introduced at the 50 region of the AAV-DJ capsid gene during
PCR amplification to promote expression of the proper ratio of capsid
proteins. Sequences were confirmed at the DNA Sequence Analysis Shared
Resource in the Molecular Microbiology and Immunology Department at
OHSU. Production of AAV-DJ VLPs in SF9 cells followed methods used for
AAV-2 (Urabe et al., 2002) using the Bac-to-Bac Baculovirus Expression
Vector System (Invitrogen, Carlsbad, CA, USA). Cultures of SF9 cells yield
2–4 mg of AAV-DJ VLPs per liter following purification by three CsCl ultracen-
trifugation gradients (Xie et al., 2004).
Heparin Binding
Heparin binding was analyzed by affinity chromatography as previously
described (Lerch and Chapman, 2012). AAV VLPs (3 mg) were injected over
a 1 ml HiTrap Heparin HP column (GE Healthcare, Waukesha, WI, USA), and
1 ml fractions were eluted with PBS supplemented with 50 mM to 1M NaCl,
in 50 mM steps. Fractions (150 ml each) were boiled in 0.01% SDS and
analyzed by dot-blot, probed with the B1 anti-AAV antibody (American
Research Products, Inc., Belmont, MA, USA). AAV-DJ and AAV-2 reactivity
to the A20 mAb was measured by native dot-blot, probed with a 1:1,000 dilu-
tion of A20 hybridoma cell supernatant. Dot blots were detected using a
peroxidase-labeled antimouse antibody and chemiluminescence substrates
(GE Healthcare).
Cryo-Electron Microscopy
Small aliquots of AAV-DJ were applied to holey carbon grids (C-flat). The
sample was then flash-frozen by plunging using a Vitrobot (FEI) at 100%
humidity and 4C and using a 2 s blot time. Data were collected on an FEI Titan
Krios at 120 keV with a range of defocus of 1.0 to 2.0 mm and an electron
dose of 15 e-/ A˚2. Images were recorded at a magnification of 120,0003 on
a 4k 3 4k pixel Gatan Ultrascan CCD camera, which resulted in a pixel size
of 0.65 A˚ at the specimen level. Processing of 36,280 particles was performed
semiautomatically using Appion (Lander et al., 2009) for picking, contrast
transfer function (CTF) estimation, and stack making. Initial particle selection
was made by the difference of Gaussians method (Voss et al., 2010) with
manual deselection of particles over carbon. CTFs were estimated with the
Automated CTF Estimation (ACE) software package (Mallick et al., 2005),
rejecting images with an estimation confidence value of less than 0.7 and flip-
ping phases for individual particles according to their ACE-estimated defocus.
EMAN (Ludtke et al., 1999) was used for initial refinement of the 3D reconstruc-
tion, using the icosahedral symmetry and an unbiased de novo starting point
calculated with the subprogram STARTICOS. Following initial refinement ofFigure 4. Distinctive Structural Features of AAV-DJ Are Concentrated
(A) A surface projection, calculated by RIVEM (Xiao and Rossmann, 2007), is colo
icosahedral equivalents covering the capsid surface and is bounded by a 5-fold
displaced 4 A˚ relative to AAV-2 because of a Ser-Gly insertion (solid black
neutralizing mouse monoclonal antibody A20 (Lochrie et al., 2006; Wobus et al.,
(B) A stereographic pair in which the VR-1 structure of AAV-DJ (green) is superimp
fragment from mAb A20. The arrow points to a steric conflict that explains the la
(C) AAV-DJ VLPs do not bind to purified A20 in a native dot-blot, whereas AAV-2
(D and E) Surface projections showing where the amino acid sequence of AAV-DJ
The experimentally visualized mAb A20 (purple) and heparin (red) footprints from
within the epitope than the primary receptor binding site.
Structure 20, 1310the EM density with EMAN, FREALIGN (Grigorieff, 2007) was used to refine
the EM density to the final structure. Euler angles for the particles were refined
with FREALIGN until convergence after 24 iterations. Resolution was esti-
mated from the EM data by FSC (Bo¨ttcher et al., 1997; Grigorieff, 2000; Harauz
and van Heel, 1986; Rosenthal and Henderson, 2003; Sousa and Grigorieff,
2007). Signal attenuation was corrected using EM-Bfactor (Ferna´ndez et al.,
2008), using a cutoff of 4.5 A˚.
Model Building and Refinement
With known crystallographic structures of homologs, modeling involved
threading the AAV-DJ sequence into the cryo-EM reconstruction, then itera-
tively selecting the most appropriate side-chain rotamer, and making needed
adjustments to the backbone using the program Coot (Emsley et al., 2010). In
a few loops, the backbone needed re-tracing where it followed a path different
from those of its homologs. Crystal structures of parental strains AAV-2
(Xie et al., 2002) and AAV-8 (Nam et al., 2007) but not AAV-9 were available
and guided the modeling. Although of slightly lower capsid sequence identity
(88% versus 92%), AAV-8 was used as the starting point for remodeling
because of its higher resolution structure. The N-terminal 16 residues of the
predominant viral protein (VP) 3 were not ordered, but it was possible to model
the rest, Val221 through Leu737, following the convention of using numbering
from the overlapping VP1 gene product.
The relative magnification, envelope correction and low-pass resolution
were least-squares optimized using a new implementation of RSRef
(Chapman, 1995) in stand-alone mode. The atomic model was then refined
by simulated annealing torsion angle optimization followed by least-squares
conjugate gradients refinement. This was performed using a real-space objec-
tive function calculated by RSRef embedded in CNS v1.3 (Bru¨nger et al., 1998).
At the core of RSRef is a comparison of density calculated from the current
atomic model with that of the 3D reconstruction. The model density was
calculated from atomic density functions that were calculated by Fourier trans-
formation of resolution-attenuated electron scattering factors, truncated to
zero at a distance from each atom of 7.5 A˚ (initial refinement) or 11.25 A˚ (final
refinement and statistics). The difference density residual and partial deriva-
tives were calculated using all map pixels within 4.5 A˚ of any atom. The new
implementation of RSRef fully supports molecular symmetry constraints
such that one protomer can be refined, accounting for the overlapping density
of any neighboring symmetry-equivalent atom within 12 A˚. For simulated
annealing, a slow cooling protocol was used starting at 5,000 K. Throughout
atomic refinement, restraints were applied to the 4 and c dihedral angles,
using an in-house program allowable_phipsi.py. This writes a list of CNS
commands for flat-bottom restraints centered on the nearest favored region
of a Ramachandran plot for each amino acid such that the restraining potential
is unfavorable for torsion angles outside a boundary approximating the allow-
able region. Isotropic thermal parameters were refined by least-squares with
RSRef in a stand-alone mode, restraining the RMS difference in B-factors
between bonded neighbors to be less than 8.5 A˚2, that is, less than the varia-
tion in the 2.6 A˚ AAV-8 crystal structure.
Duringmanual readjustmentsmade in Coot (Emsley et al., 2010), the original
image stack was being reprocessed with FreAlign (Grigorieff, 2007). After
reprocessing, loop residues Asn262–Ser269 and Thr453–Thr457 were resolved
with continuous density and were modeled into a configuration that was
different from both AAV-2 and AAV-8. The same steps of atomic refinement
were repeated with the now-complete atomic model and the improved
reconstruction.in a Dominant Antigenic Site
red by distance from the viral center (blue to red). The triangular area is 1 of 60
axis (pentagon) and 3-folds (triangle). The VR-I loop (dashed black outline) is
outline), disrupting the footprint of the AAV-2 binding site (yellow outline) of
2000), as visualized by cryo-EM (McCraw et al., 2012).
osed on the crystal structure of AAV-2 (red) and the envelope of a bound FAb’
ck of A20 binding to AAV-DJ.
is readily detected.
differs from AAV-2 (D) and where the Ca differences are greater than 1.5 A˚ (E).
AAV-2 are superimposed. (D and E) Emphasize that AAV-DJ is more unique
–1320, August 8, 2012 ª2012 Elsevier Ltd All rights reserved 1317
Structure
Cryo-EM Structure of AAV-DJFigureswere generated using the PyMolmolecular graphics server (DeLano,
2002). Capsid electrostatic potentials were calculated with APBS (Baker et al.,
2001), first over a coarse grid for assembled capsids and then refined on a fine
mesh near the icosahedral 3-fold axis, before projecting onto the surface for
display in PyMol (DeLano, 2002).
ACCESSION NUMBERS
The AAV-DJ reconstruction has been deposited in the EM Data Bank with
accession code EMD-5415, and the AAV-DJ coordinates have been deposited
in the Protein Data Bank (PDB) with the accession code 3J1Q.
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